| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Other | 1,273 | 1,088 |
| Net cash provided by (used in) investing activities | 308,247 | 191,065 |
| Proceeds from the issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net | 0 | 0 |
| Proceeds from the issuance of common stock in connection with at-the-market offering, net | 79,728 | 79,728 |
| Proceeds from the issuance of common stock under equity plan awards, net of tax | -4,080 | -4,078 |
| Proceeds from issuance of equity from noncontrolling interest | 0 | - |
| Net cash provided by financing activities | 83,808 | 83,806 |
| Effect of exchange rate changes on cash | 4,656 | 4,362 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 30,540 | 4,485 |
| Cash and cash equivalents at beginning of period | 184,159 | - |
| Cash and cash equivalents at end of period | 214,699 | - |
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)